Student's Journal of Health Research Africa
Vol. 4 No. 12 (2023): December 2023 Issue
https://doi.org/10.51168/sjhrafrica.v4i12.977
Narrative Review

A NARRATIVE REVIEW OF COMPREHENSIVE INSIGHTS INTO ACUTE CORONARY SYNDROME.

Birendra Kumar*
MD, DM Cardio, Paras HMRI Hospital, Patna, Bihar, India.

ABSTRACT

Acute Coronary Syndrome (ACS) encompasses a spectrum of myocardial ischemic conditions, including unstable angina, Non-ST-Elevation Myocardial Infarction (NSTEMI), and ST-Segment Elevation Myocardial Infarction (STEMI). Understanding the multifaceted nature of ACS is essential for effective management and improved patient outcomes.

This narrative review provides a comprehensive exploration of ACS, covering various facets crucial to its comprehension. The article delves into the diverse risk factors contributing to ACS development and delve into the intricate pathophysiological mechanisms that underlie its manifestation. Additionally, it elucidate the wide-ranging clinical presentations and symptoms commonly encountered in ACS patients. A critical examination of diagnostic challenges is also undertaken, with a specific focus on cardiac biomarkers and electrocardiographic changes, addressing the complexities and variations in these key diagnostic elements.

This narrative review offers an extensive overview of Acute Coronary Syndrome, shedding light on its multifactorial etiology, intricate pathophysiology, and diverse clinical presentations. By addressing diagnostic nuances related to cardiac biomarkers and electrocardiographic changes, this review contributes to a deeper understanding of the challenges in ACS diagnosis. A comprehensive grasp of ACS is essential for healthcare professionals to facilitate timely interventions and enhance patient care, ultimately leading to improved clinical outcomes.

Keywords: *Acute Coronary Syndrome (ACS), ST-Segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina*
Submitted: 2023-12-22 Accepted: 2023-12-23

*Corresponding author: Birendra Kumar**
Email: kbirendra97@gmail.com
MD, DM Cardio, Paras HMRI Hospital, Patna, Bihar, India

INTRODUCTION

Coronary artery disease, characterized by the presence of atherosclerotic plaque within the coronary arteries, presents an enduring and substantial risk to individuals. Remarkably, the incidence of coronary artery disease events transpires at an approximate rate of one occurrence every 25 seconds, thereby emphasizing the imperative nature of continuous endeavors to enlighten healthcare practitioners and the general populace regarding its predisposing factors, manifestations, and therapeutic interventions.

The present pathological state, distinguished by the constriction of coronary arteries, leads to a diminished circulation of blood to the cardiac muscle, thereby causing deprivation of essential oxygen supply. As a result, it has the potential to initiate a series of potentially fatal occurrences. One particular consequence is Acute Coronary Syndrome (ACS), a phrase formulated to more accurately illustrate the abrupt initiation and gravity of myocardial ischemia—a sudden decrease in blood flow to the cardiac muscle. Within the spectrum of ACS, both Unstable Angina and Myocardial Infarction (MI) signify crucial phases of this cardiac emergency.

The clinical manifestations of ACS encompass a continuum of severity, spanning from unstable angina to non-ST-segment elevation Myocardial Infarction (NSTEMI) to ST-segment elevation Myocardial Infarction (STEMI). NSTEMI and unstable angina commonly manifest as a consequence of partial or intermittent obstructions within the coronary arteries. Conversely, STEMI arises from a total occlusion of these arteries. As per the findings of the American Heart Association (AHA), it is projected that a total of 785,000 individuals residing in the United States will encounter a MI within the current year. Among this population, approximately 500,000 individuals are anticipated to undergo recurrent episodes of MI. In the year 2006, an estimated 1.4 million individuals were discharged from healthcare facilities with a primary and/or secondary diagnosis of ACS. Among these patients, approximately 537000 presented with unstable angina, while 810000 were diagnosed with either NSTEMI and/or STEMI. It is worth observing that some individuals presented with both unstable angina and MI [1].

The practice guidelines and performance measures have been recently updated by the American College of Cardiology (ACC) and the American Heart Association (AHA) in order to provide clinicians with guidance on delivering standardized care to patients presenting with symptoms of any stage of ACS [2]. It is noteworthy to acknowledge that nurses, irrespective of their specialization in cardiovascular care, assume crucial responsibilities in the identification of patients who are susceptible to ACS, facilitating the process of diagnosis and treatment, and delivering educational interventions that contribute to improved patient outcomes. A significant number of

patients who have been diagnosed with NSTEMI or unstable angina may be receiving medical attention from physicians who specialize in fields other than cardiology. Consequently, it becomes imperative for nurses to actively encourage and support compliance with evidence-based practice guidelines.

Ethical Considerations

In the process of conducting this narrative review, ethical considerations were upheld in accordance with established ethical guidelines for research and literature review. No primary data or patient records were collected or accessed during this study, ensuring patient privacy and confidentiality. The information presented in this review is based on publicly available literature, guidelines, and statistical data from reputable sources, with proper citations and references to acknowledge the original authors' work and contributions. The study aims to disseminate knowledge and promote awareness of Acute Coronary Syndrome (ACS) and its management, emphasizing the importance of evidence-based practice guidelines and ethical patient care.

PATHOPHYSIOLOGY

Within the domain of medical comprehension, it is imperative to explore the intricate mechanisms that underlie ACS. The underlying cause that universally links all cases of ACS is the disruption or degradation of the fibrous cap encasing a plaque within a coronary artery. This pivotal occurrence elicits a series of physiological reactions with significant implications.

Primary and foremost, the compromised fibrous cap precipitates platelet aggregation and adhesion within the coronary artery. The aggregation of platelets facilitates the initiation of localized thrombosis, wherein the formation of a blood clot takes place in close proximity to the rupture of the plaque [3]. The ramifications are extensive, encompassing not only thrombosis as well as vasoconstriction, which entails the constriction of the impacted coronary artery.

Moreover, the ramifications transcend the location of plaque rupture. Distal thrombus embolization may manifest as the detachment of fragments from the thrombus, subsequently traversing in a downstream direction. This phenomenon has the potential to induce obstructions within narrower blood vessels, thereby precipitating subsequent complications. The likelihood of plaque rupture is influenced by various factors. It is worth noting that atherosclerotic plaques characterized by a substantial accumulation of lipids within their structure and a thin layer of fibrous tissue covering them are more susceptible to experiencing a rupture event. These aforementioned characteristics render them more prone to the influences exerted upon them within the arterial milieu.

The formation of a thrombus within the coronary artery that is affected, in conjunction with the vasoconstriction caused by the release of serotonin and thromboxane A2 from activated platelets, ultimately leads to myocardial ischemia [4]. The present condition manifests as a result of diminished coronary blood flow, wherein the thrombus impedes the transit of oxygenated blood to the myocardium. Myocardial ischemia, marked by insufficient blood flow to the heart muscle, holds profound importance in ACS scenarios. Timely intervention is imperative to alleviate the deleterious consequences associated with this condition.

DIAGNOSIS

Clinical presentation

The consideration of ACS as a potential diagnosis is warranted in all individuals who show symptoms indicative of myocardial ischemia. The clinical manifestations of ischemia encompass a diverse array of symptoms, which may manifest in different combinations. These include but are not limited to chest pain, discomfort in the upper extremities, mandible, or epigastric region, dyspnea, profuse sweating, fatigue, syncope, and nausea. The pain and uneasiness commonly experienced during an ACS event may manifest during physical exertion or even at rest, and typically presents as a diffuse sensation rather than being localized to a specific area. Pain that extends to the left arm, right shoulder, or bilateral upper extremities is indicative of a higher likelihood of MI, as is the presence of pain accompanied by diaphoresis [5]. The aforementioned symptoms lack specificity for MI and are not universally present in all individuals undergoing an ACS episode. Atypical manifestations of ACS may manifest in specific patient cohorts, including but not limited to the female demographic, geriatric individuals, those with diabetes mellitus, or individuals in the postoperative period. In the aforementioned scenarios, ACS may manifest in conjunction with cardiac arrest, palpitations, or as an asymptomatic clinical presentation [6].

Cardiac biomarkers

Cardiac troponins, such as troponin I or T and the MB fraction of creatine kinase (CKMB), are markers of myocardial damage but do not specify the cause or differentiate between ischemic and nonischemic factors. Elevated levels can result from various conditions like heart failure, pulmonary embolism, myocarditis, and renal disease, making them insufficient for diagnosing MI.

Troponin is the preferred biomarker due to its high medical sensitivity and specificity for myocardial tissue. Troponin elevation is precisely characterized by levels surpassing the 99th percentile of a typical reference population. Sensitive assays exhibit positive likelihood ratios ranging from 11 to 14 and negative likelihood ratios ranging from 0.06 to 0.15, respectively. To distinguish acute from chronic troponin

elevations linked to structural heart disease, detecting rising or falling levels is crucial. Troponin should be checked on initial evaluation, within 6 hrs of symptom onset, and between 6-12 hours afterward due to delayed increases [7]. It's important to highlight that troponin levels can stay elevated for as long as 2 weeks following the onset of myocardial damage. In cases where troponin testing isn't accessible, CKMB can serve as an alternative measure. For comprehensive ACS assessment, it's recommended to evaluate both troponin and CKMB due to their dynamic concentrations and diagnostic significance throughout the course of the condition.

ECG changes

ECG deviations that may suggest myocardial ischemia include alterations in the PR segment, the ST-segment, and the QRS complex. Evaluating these ECG changes can help estimate the timing of the event, the extent of myocardial involvement, patient prognosis, and appropriate treatment strategies. The hallmark sign of a STEMI is ST-segment elevation on the ECG. However, like cardiac biomarkers, the ECG alone may not be sufficient for diagnosing an acute MI. Sensitivity and specificity can be improved by performing serial ECG assessments. It's crucial to be aware that ECG alterations, including ST segment deviations, can also manifest in other conditions such as left ventricular hypertrophy, left bundle branch block, or acute pericarditis [5].

Differential Diagnosis

It's crucial to remember that myocardial infarction (MI) signifies myocardial necrosis due to myocardial ischemia. Other clinical conditions, such as pericarditis, mitral valve prolapse, and dissecting aortic aneurysm, are recognized as non-ischemic cardiac reasons of myocardial injury. Consequently, these conditions do not meet the criteria for ACS. Furthermore, it is important to note that there exist various noncardiac conditions that can present with symptoms resembling those of ACS. These conditions encompass esophageal discomfort, musculoskeletal pain, anxiety, or pulmonary embolism. The accurate identification of the etiology of a patient's presenting signs and symptoms is imperative in order to establish an optimal course of action for their management [5].

RISK FACTORS

The risk for developing coronary artery disease is influenced by non-modifiable factors, namely gender, age, family medical history, and racial or ethnic background. Males exhibit a greater susceptibility in comparison to females. Males aged 45 and above, and females aged 55 and above, along with individuals who have a 1st degree men or women relative diagnosed with coronary artery disease before the ages of 55 or 65 respectively, are considered to be at an elevated risk. Risk factors that can be modified include the presence of low-density lipoprotein cholesterol (LDL-C), elevated serum cholesterol, and triglyceride levels, in addition to lower levels of high-density lipoprotein cholesterol (HDL-C). Furthermore, the concurrent presence of cigarette smoking, type 2 diabetes, obesity, hypertension, stress, and sedentary lifestyle serves as contributing factors to these modifiable risk factors.

DRUG THERAPY

The primary pharmacological intervention for angina pectoris entails the administration of a combination of medications, namely aspirin, oxygen supplementation, morphine sulfate, and nitroglycerin. Aspirin should be administered promptly (162 to 325 mg) unless contraindicated due to conditions like peptic ulcers or allergies. Oxygen (2 to 4 L/min) should maintain SaO_2 above 90% [8]. Sublingual administration of nitroglycerin tablets at a dosage range of 0.3 to 0.4 mg is recommended, with the option to repeat this regimen up to three times within a five-minute interval. In the event that the initial administration of medication does not yield any alleviation and the patient is not currently situated within a facility providing immediate medical attention, it is advised to promptly contact the emergency helpline. Nitroglycerin causes vasodilation, reducing myocardial oxygen demand, but monitor for hypotension [2].

In the event that pain continues to endure subsequent to the administration of nitroglycerin, it may be deemed appropriate to administer morphine sulfate (2-to-4-mg intravenous push) at intervals of five to fifteen minutes, until the pain is adequately managed. Morphine causes vasodilation and relieves pain and anxiety but monitor for hypotension and respiratory depression [8].

Adjunctive pharmacotherapy in ACS encompasses the utilization of β-adrenergic receptor blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, clopidogrel, and glycoprotein IIb/IIIa inhibitors. β-blockers, although subject to controversy, have demonstrated potential in reducing the occurrence of reinfarction and arrhythmias [9]. However, it is important to note that their impact on overall mortality rates, particularly in individuals with heart failure, remains inconclusive. ACE inhibitors have been shown to effectively mitigate left ventricular dysfunction and mortality rates, rendering them advantageous in individuals with ACS and comorbid diabetes mellitus.

The administration of statin therapy is indicated in cases where the LDL-C levels exceed the threshold of 100 mg/dL. Clopidogrel may be employed as a therapeutic option in individuals presenting with hypersensitivity to aspirin. Glycoprotein IIb/IIIa inhibitors effectively impede the process of platelet aggregation, rendering them valuable in

the context of invasive diagnostic procedures, particularly in patients who are slated to undergo percutaneous coronary intervention (PCI) [2]. The available anticoagulant options encompass unfractionated heparin, enoxaparin, fondaparinux, and bivalirudin, each with distinct characteristics that warrant consideration in light of individualized risk profiles.

MANAGEMENT OF ACUTE CORONARY SYNDROME

The management of ACS necessitates a comprehensive and multifaceted approach with the primary objective of expeditiously diagnosing, stabilizing, and administering appropriate treatment to patients in order to enhance clinical outcomes. The management strategies implemented in this context are derived from clinical guidelines issued by esteemed sources such as the European Society of Cardiology (ESC). These strategies are meticulously customized to suit the unique condition and risk factors of each individual patient.

The primary objective of Initial Stabilization and Diagnosis entails promptly achieving patient stabilization while concurrently establishing a definitive diagnosis of ACS. The aforementioned procedures encompass the continuous observation of essential physiological parameters, the execution of an electrocardiographic assessment, and the evaluation of cardiac biomarkers such as troponin concentrations. The management of ischemic pain primarily involves the administration of pharmacological agents to alleviate symptoms [10].

Vasodilators, such as nitroglycerin, are commonly employed to promote vasodilation, thereby enhancing blood flow to the affected area. Additionally, opioids, including morphine, are frequently utilized to provide effective pain relief in individuals experiencing ischemic pain. In individuals deemed high-risk or those experiencing persistent symptoms, the implementation of early invasive approaches encompassing cardiac catheterization and revascularization interventions such as angioplasty and stent placement may be contemplated. It is imperative to engage in ongoing surveillance of vital signs, electrocardiogram (ECG) readings, and cardiac biomarkers throughout the course of treatment. This practice serves the purpose of evaluating the patient's reaction to the intervention and identifying any potential complications [10].

Administration of dual antiplatelet therapy comprising aspirin and P2Y12 inhibitors (e.g., clopidogrel) is employed as a preventive measure against the occurrence of subsequent clot formation in patients undergoing antiplatelet and anticoagulant therapy. Anticoagulants, such as heparin, may also find utility in the management of the condition. The selection of medications for the management of ACS is contingent upon the classification of the condition as either STEMI or NSTEMI [11].

In accordance with established therapeutic guidelines, healthcare providers may prescribe a range of pharmaceutical agents, including beta-blockers, statins, glycoprotein IIb/IIIa inhibitors, and ACE inhibitors. The primary objectives of administering these medications are to address underlying pathophysiological processes, mitigate the likelihood of adverse outcomes, and promote optimal patient outcomes. It is strongly advised to motivate patients to embrace a cardiovascular-optimized lifestyle, encompassing the cessation of smoking, alterations to dietary patterns, consistent engagement in physical activity, and effective management of risk factors [11].

CONCLUSION

Acute Coronary Syndrome (ACS) is a serious, life-threatening disease that affects many people annually. As MI hospital admissions drop, ACS identification and prevention remain crucial to public health. Our understanding of ACS pathogenesis and medical therapy have improved in recent years. ACS early therapy requires many important steps. Risk assessment, Dual Antiplatelet Therapy (DAPT), anticoagulant medications, and adjunctive therapies are all part of the patient's comprehensive management. A key choice must be made between early invasive intervention and conventional therapy. Long-term therapy of ACS requires evidence-based guidelines. Additionally, management must be tailored to each patient's needs. This comprehensive method ensures that patients receive the best care to reduce ACS risks and improve recovery.

Key lesson learnt:

The case study on Acute Coronary Syndrome (ACS) imparts several crucial lessons. It underscores the substantial burden of ACS and the need for continuous education about its risk factors and management. Exploring ACS's pathophysiology, it illuminates the role of plaque rupture, thrombosis, and physiological reactions. Diagnosis relies on diverse symptoms, cardiac biomarkers, and ECG changes, with attention to differential diagnosis. Both non-modifiable and modifiable risk factors are discussed. Drug therapy encompasses aspirin, oxygen, nitroglycerin, and morphine, tailored to individual cases. Managing ACS involves multifaceted approaches, early invasive interventions, and long-term care, all emphasizing evidence-based guidelines and individualized treatment. The study highlights the evolving understanding of ACS and the importance of prevention, patient education, and risk reduction in public health.

REFERENCES

1. Lloyd-Jones D, et al. Heart disease and stroke statistics— 2009 update: a report from the American Heart Association Statistics Committee and Stroke

Statistics Subcommittee. Circulation 2009; 119(3):e21-e181.
2. Anderson JL, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction). Circulation 2007;116(7):e148-e304.
3. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. European Heart Journal: Acute Cardiovascular Care. 2012 Apr 1;1(1):60-74.
4. Machado AP, Saavedra JA, Ribeiro C. Insights into the role of thromboxane A2 and serotonin in the pathogenesis of unstable angina. Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia= Portuguese Journal of Cardiology: an Official Journal of the Portuguese Society of Cardiology. 1994 Dec 1;13(12):935-46.
5. Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998;280:1256 – 1263.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020 –2035.
7. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858 – 867.
8. Hazinski MF, et al., editors. Handbook of emergency cardiovascular care for healthcare providers. Dallas: American Heart Association; 2008.
9. Krumholz HM, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction). J Am Coll Cardiol 2008;52(24):2046-99.
10. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. InMayo Clinic Proceedings 2009 Oct 1 (Vol. 84, No. 10, pp. 917-938). Elsevier.
11. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European heart journal. 2023 Oct 7;44(38):3720-826.

Publisher details:

Publishing Journal: Student's Journal of Health Research Africa.
Email: studentsjournal2020@gmail.com or admin@sjhresearchafrica.org

(ISSN: 2709-9997)

Publisher: SJC Publishers Company Limited
Category: Non-Government & Non-profit Organisation
Contact: +256775434261(WhatsApp)
Email: admin@sjpublisher.org
Website: https://sjpublisher.org
Location: Wisdom Centre Annex, P.O. BOX. 701432 Entebbe, Uganda, East Africa.